We are live on
!
Find out more
DTC
Deep Track Capital Portfolio holdings
AUM
$6.12B
1-Year Est. Return
144%
This Fund
S&P 500
This Quarter
Est. Return
+33.9%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.18B
AUM Growth
+$662M
(+44%)
Cap. Flow
+$335M
Cap. Flow
% of AUM
15.36%
Top 10 Holdings %
Top 10 Hldgs %
41.73%
Holding
72
New
21
Increased
12
Reduced
21
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$102M |
| 2 |
Ascendis Pharma A/S
ASND
|
+$75.8M |
| 3 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$67.9M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
+$54.9M |
| 5 |
Aurinia Pharmaceuticals
AUPH
|
+$49.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$183M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$64.8M |
| 3 |
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
|
+$40.7M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
+$24.4M |
| 5 |
Fate Therapeutics
FATE
|
+$20.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ISEE
1
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $126M | 5.75% |
7,000,000
+2,500,000
| +56% | +$32.8M |
|
|
2
Jazz Pharmaceuticals
JAZZ
$16.1B
| $115M | 5.26% |
861,000
+361,000
| +72% | +$54.9M |
|
|
3
CALL
Ascendis Pharma A/S
ASND
$16.7B
| $103M | 4.73% |
+1,000,000
| New | +$94.8M |
|
4
Travere Therapeutics
TVTX
$5.13B
| $98.6M | 4.51% |
4,000,000
+419,300
| +12% | +$10.8M |
|
5
NovoCure
NVCR
$1.79B
| $98.3M | 4.5% |
1,293,761
-47,539
| -4% | -$3.71M |
|
|
HZNP
6
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $90.5M | 4.15% |
+1,462,800
| New | +$102M |
|
|
7
Ascendis Pharma A/S
ASND
$16.7B
| $82.6M | 3.78% |
+800,000
| New | +$75.8M |
|
|
SWTX
8
DELISTED
SpringWorks Therapeutics
SWTX
| $67.6M | 3.1% |
+2,369,210
| New | +$67.9M |
|
|
BCYC
9
Bicycle Therapeutics
BCYC
$272M
| $67.5M | 3.09% |
2,900,000
| – | – |
|
10
BioMarin Pharmaceuticals
BMRN
$12B
| $62.6M | 2.87% |
738,863
+84,498
| +13% | +$7.52M |
|
|
KDNY
11
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $59M | 2.7% |
3,000,000
-430,110
| -13% | -$8.63M |
|
12
Immunovant
IMVT
$7.82B
| $55M | 2.52% |
9,860,246
+405,246
| +4% | +$1.98M |
|
|
AGEN
13
Agenus
AGEN
$275M
| $54M | 2.47% |
1,341,259
+208,059
| +18% | +$10.6M |
|
14
Beam Therapeutics
BEAM
$2.66B
| $47.6M | 2.18% |
1,000,000
-250,000
| -20% | -$14.3M |
|
15
Kura Oncology
KURA
$789M
| $43.5M | 1.99% |
3,186,083
-511,886
| -14% | -$7.9M |
|
|
16
Aurinia Pharmaceuticals
AUPH
$1.92B
| $42.7M | 1.96% |
+5,677,372
| New | +$49.1M |
|
17
Dyne Therapeutics
DYN
$4.17B
| $40.4M | 1.85% |
3,184,200
-315,800
| -9% | -$3.62M |
|
18
Viridian Therapeutics
VRDN
$2.13B
| $40.4M | 1.85% |
1,970,290
+800,000
| +68% | +$14.4M |
|
|
RPTX
19
DELISTED
Repare Therapeutics
RPTX
| $37.9M | 1.74% |
3,127,667
+420,005
| +16% | +$5.41M |
|
20
Acumen Pharmaceuticals
ABOS
$158M
| $37.9M | 1.74% |
3,778,818
+678,818
| +22% | +$3.89M |
|
|
ESPR
21
DELISTED
Esperion Therapeutics
ESPR
| $37.8M | 1.73% |
5,636,587
-363,413
| -6% | -$2.5M |
|
22
Nkarta
NKTX
$155M
| $37M | 1.7% |
2,814,844
| – | – |
|
23
Heron Therapeutics
HRTX
$92.6M
| $36.1M | 1.65% |
+8,548,387
| New | +$33.4M |
|
|
ISEE
24
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $35.9M | 1.64% |
+2,000,000
| New | +$26.3M |
|
25
Edgewise Therapeutics
EWTX
$4.29B
| $33.2M | 1.52% |
+3,374,394
| New | +$34.1M |
|
Similar funds
AWA
ACM
CIS
AA
JWBC
EMPI
HPG
B
Deep Track Capital's Q3 2022 Portfolio in Review
As of Q3 2022, Deep Track Capital held 72 positions worth $2.18B, up 44% from $1.52B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Deep Track Capital deployed $335M of net new capital in Q3 2022, opening 21 new positions and adding to 12 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 1,462,800 shares worth $90.5M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 95% a quarter earlier.
On the sell side, the largest reduction was Global Blood Therapeutics, Inc., an estimated $183M trimmed.
- Deep Track Capital's largest Q3 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 1,462,800 shares worth $90.5M.
- Deep Track Capital added most to Jazz Pharmaceuticals in Q3 2022, an estimated $54.9M increase.
- Deep Track Capital's biggest Q3 2022 reduction was Global Blood Therapeutics, Inc., cutting an estimated $183M.
- Deep Track Capital fully exited Madrigal Pharmaceuticals in Q3 2022, selling an estimated $64.8M.
- Deep Track Capital's ten largest holdings make up 42% of its $2.18B portfolio in Q3 2022.
- Deep Track Capital opened 21 new positions and closed 7 in Q3 2022.
- Deep Track Capital's portfolio value rose 44% quarter-over-quarter to $2.18B.
Based on Deep Track Capital's 13F filing for Q3 2022, filed 14 Nov 2022.